Loading stock data…
APVO
$4.92+0.07 (+1.44%)
Market ClosedLast close May 1
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aptevo Therapeutics Inc. in the Healthcare sector is trading at $4.92. The stock is currently near its 52-week low of $3.80, remaining 75.5% below its 200-day moving average. Technical signals show neutral RSI of 55 and bullish MACD crossover, explaining why APVO maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 55) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.92
Potential Upside
5%
Whystock Fair Value$5.17
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$21.00+326.8%
Range$21.00 – $21.00
Fundamentals
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using A...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.51
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
36.80%
Volume
Today's trading volume
4,236
Recent News
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why
Aptevo Therapeutics (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Health care stocks were edging up late Friday afternoon with the NYSE Health Care Index and the Stat
Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Aptevo Therapeutics (APVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Wall Street Set to Open Higher Thursday; Jobless Claims Fall as Manufacturing Index Rebounds
US stocks look set to open higher Thursday following a lower-than-expected jobless claims report and
Aptevo Meets Nasdaq $2.5M Equity Requirement
Aptevo Therapeutics Inc. (NASDAQ:APVO) is among the best get rich quick stocks to buy now. As per the announcement last Tuesday, Aptevo Therapeutics Inc. (NASDAQ:APVO) has regained compliance with the Nasdaq Listing Rule 5550(b)(1), which requires listed companies to sustain at least $2.5 million in stockholders’ equity. The company received a green signal from the […]